ADVERTISEMENT
40-Gene Expression Profile Test Effective Adjunct for cSCC Risk Stratification
A 40-gene expression profile (40-GEP) test can be a useful adjunct to enhance cutaneous squamous cell carcinoma (cSCC) risk stratification, concluded a poster abstract at the Society of Dermatology Physician Assistants Annual Summer Dermatology Conference 2021.
Arron et al aimed to demonstrate independent prognostic value of the 40-GEP with existing risk assessment methods as well as report on the early clinical usage of the test. They examined formalin-fixed paraffin-embedded (FFPE) cSCC samples by centralized pathology review; the FFPE samples were then assayed by the 40-GEP test. To evaluate clinical validation, archival cSCC tissue with verified clinicopathologic information and outcomes data were assayed by of the 40-GEP test. Clinical usage was evaluated by recording 40-GEP result and patient risk factors, including lesion location, 2 cm or greater diameter, poorly defined borders, patient immunosuppression, tumor growth, among others.
Upon analysis, the 40-GEP was found to classify patients based on risk for metastasis, demonstrating independent prognostic value in multivariate analysis. The research group also demonstrated that test had high technical reliability, with 96.3% of samples having a successful GEP.
“Incorporating 40-GEP test results in clinical assessments with traditional clinicopathological
risk factors can improve stratification of high-risk…patients [with cSCC] and contribute to risk-appropriate surveillance and treatment decisions,” concluded the study authors.Reference
Arron ST, Wysong A, Fitzgerald AL, et al. Real-world clinical usage data demonstrates appropriate utilization of the prognostic 40-gene expression profile test for cutaneous squamous cell carcinoma with one or more risk factors. Poster presented at: Society of Dermatology Physician Assistants Annual Summer Dermatology Conference 2021; July 22-25, 2021; Chicago, IL.
